Health
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary outcome measures, and a favorable safety profile1 Novartis plans to submit to health authorities globally in early 2026 If approved, ianalumab could become first targeted treatment for this heterogeneous, systemic autoimmune disease Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s diseas
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":287,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jVHT.jc1r.9_PBg7JQVa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":287,"height":55}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 ","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Data showed consistent improvements across secondary outcome measures, and a favorable safety profile1 ","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Novartis plans to submit to health authorities globally in early 2026 ","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"If approved, ianalumab could become first targeted treatment for this heterogeneous, systemic autoimmune disease","length":112,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":417,"olType":false},{"type":"text","content":"Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease2, at a late-breaker presentation during the American College of Rheumatology Convergence congress1.","length":246,"tagName":"p"},{"type":"text","content":"Ianalumab 300 mg monthly delivered a clinically meaningful benefit in the global NEPTUNUS-1 and NEPTUNUS-2 Phase III trials, showing both improvement in disease activity and reductions in patient burden1. Compared to placebo, ianalumab achieved a numerically greater reduction in disease activity by Week 16 with improvements sustained through Week 52 as measured by the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI)1.","length":429,"tagName":"p"},{"type":"text","content":"“Sjögren’s disease is a debilitating autoimmune condition affecting multiple organs causing a wide spectrum of symptoms such as dryness, fatigue, pain, and an increased risk of lymphoma – that together may create a substantial disease burden,” says Professor Xavier Mariette...